Please login to the form below

Not currently logged in
Email:
Password:

esketamine

This page shows the latest esketamine news and features for those working in and with pharma, biotech and healthcare.

NICE knocks back J&J’s depression nasal spray Spravato

NICE knocks back J&J’s depression nasal spray Spravato

Spravato (esketamine) is a glutamate NMDA receptor modulator – when it was first approved by the FDA in March last year it was quickly hailed as an end to a drought in ... Meindert Boysen, director of the centre for health technology evaluation at NICE

Latest news

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...